Your browser doesn't support javascript.
loading
An Innovative Immunotherapy Vaccine with Combination Checkpoint Blockade as a First Line Treatment for Glioblastoma in the Context of Current Treatments.
Coxon, Andrew T; Johanns, Tanner M; Dunn, Gavin P.
Afiliação
  • Coxon AT; Andrew T. Coxon, MS2, Department of Neurological Surgery; Tanner M. Johanns, MD, PhD, Assistant Professor of Medicine, Division of Medical Oncology; and Gavin P. Dunn, MD, PhD, (above), Associate Professor of Neurological Surgery, Director of Brain Tumor Immunology and Therapeutics, and the Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs; all are at Washington University School of Medicine, St. Louis, Missouri.
  • Johanns TM; Andrew T. Coxon, MS2, Department of Neurological Surgery; Tanner M. Johanns, MD, PhD, Assistant Professor of Medicine, Division of Medical Oncology; and Gavin P. Dunn, MD, PhD, (above), Associate Professor of Neurological Surgery, Director of Brain Tumor Immunology and Therapeutics, and the Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs; all are at Washington University School of Medicine, St. Louis, Missouri.
  • Dunn GP; Andrew T. Coxon, MS2, Department of Neurological Surgery; Tanner M. Johanns, MD, PhD, Assistant Professor of Medicine, Division of Medical Oncology; and Gavin P. Dunn, MD, PhD, (above), Associate Professor of Neurological Surgery, Director of Brain Tumor Immunology and Therapeutics, and the Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs; all are at Washington University School of Medicine, St. Louis, Missouri.
Mo Med ; 117(1): 45-49, 2020.
Article em En | MEDLINE | ID: mdl-32158049
ABSTRACT
Glioblastoma is a devastating disease with a dismal prognosis. While recent advancements in cancer immunotherapy have led to improvements in treating other types of cancer, patients with glioblastoma have not benefited from these new therapies and techniques. Fortunately, neurosurgeons and oncologists at Washington University School of Medicine conducting a cutting edge clinical trial are looking to overcome these persistent challenges in treating glioblastoma through combining a personalized vaccine with new immunotherapy drugs.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioblastoma / Vacinas Anticâncer / Imunoterapia Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioblastoma / Vacinas Anticâncer / Imunoterapia Idioma: En Ano de publicação: 2020 Tipo de documento: Article